(Q37393870)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

14 September 2020

Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

14 September 2020

1 reference

14 September 2020

KIT proto-oncogene, receptor tyrosine kinase

1 reference

2 August 2019

1 reference

14 September 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Michał Mączewski

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

5

Cezary Szczylik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

4

Lubomir Bodnar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Bartłomiej Grala

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

1 reference

7 October 2009

8 references

3 April 2019

31 July 2019

2 August 2019

28 September 2019

15 December 2019

18 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

14 September 2020

Journal of Experimental & Clinical Cancer Research

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

14 September 2020

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 2.0 Generic

9 February 2020

copyright license

7 references

3 April 2019

31 July 2019

2 August 2019

28 September 2019

15 December 2019

18 December 2019

on focus list of Wikimedia project

14 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Genetic basis of kidney cancer: a model for developing molecular-targeted therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Sorafenib in advanced clear-cell renal-cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Application of molecular diagnostic techniques to renal epithelial neoplasms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Molecular genetics of familial renal cell carcinoma syndromes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Overexpression of KIT in chromophobe renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Chromophobe renal cell carcinoma with extensive calcification and ossification

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Human chromophobe cell renal carcinoma.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: a retrospective analysis on computed tomography and magnetic resonance imaging studies.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Parvalbumin Is Constantly Expressed in Chromophobe Renal Carcinoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2764641

Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma

3 December 2018

1 reference

12 December 2020

Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas

1 reference

12 December 2020

Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience

1 reference

12 December 2020

Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group

1 reference

12 December 2020

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

12 December 2020

Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-9966-28-134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 February 2020

1053576315

0 references

Fatcat ID

release_bjavqucw5rftzkmmuu4xunfkta

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bjavqucw5rftzkmmuu4xunfkta

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

19811659

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19811659%20AND%20SRC:MED&resulttype=core&format=json